Pulsing with blast cell lysate or blast-derived total rna reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells;Pulsen mit Blastenzelllysat oder Blasten-Gesamt-RNA richtet die durch dendritische Zellen vermittelte Aktivität von Zytokin-induzierten Killerzellen gegen allogene akute myeloische Zellen

GMS German Medical Science

Volumn 9, Issue , 2011, Pages

  Schöttker, Björn ^a   Schmidt Wolf, Ingo G H ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Aml; Blast cell lysate; Blast derived RNA; Cytokine induced killer cells; Dendritic cells

Indexed keywords

EID: 84875354022     PISSN: 16123174     EISSN: None     Source Type: Journal    
DOI: 10.3205/000141     Document Type: Article

References (63)

1. Estey EH. Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Semin Hematol. 1995;32(2):132-51.
2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al. Graft-versusleukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555-62.
3. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E 3rd. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903. DOI: 10.1056/NEJM199410063311402
4. O'Reilly RJ. Allogenic bone marrow transplantation: current status and future directions. Blood. 1983;62(5):941-64.
5. Ringdén O, Sundberg B, Lönnqvist B, Tollemar J, Gahrton G, Nilsson B. Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. Bone Marrow Transplant. 1988;3(4):281-90.
6. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydlo R, Zwaan FE. Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A report by the EBMT Leukaemia Working Party. Br J Haematol. 1991;79(4):567-74. DOI: 10.1111/j.1365-2141.1991.tb08083.x
7. Mrsíc M, Horowitz MM, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Prentice HG, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992;9(4):269-75.
8. Gratwohl A, Hermans J, Apperley J, Arcese W, Bacigalupo A, Bandini G, di Bartolomeo P, Boogaerts M, Bosi A, Carreras E, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86(2):813-8.
9. Kolb HJ, Holler E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol. 1997;9(2):139-45. DOI: 10.1097/00001622-199703000-00006
10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041-50.
11. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leucocyte infusions after chemotherapy for patients relapsing with acute leukaemia following allogeneic BMT. Bone Marrow Transplant. 1993;11(2):109-11.
12. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9(1):10-6. DOI: 10.1016/S0952-7915(97)80153-7
13. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med. 1999;5(4):405-11. DOI: 10.1038/7403
14. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90(9):3245-87.
15. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-96. DOI: 10.1146/annurev.iy.09.040191.001415
16. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673):245-52. DOI: 10.1038/32588
17. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-58. DOI: 10.1146/annurev.immunol.14.1.233
18. Romani N, Koide S, Crowley M, Witmer-Pack M, Livingstone AM, Fathman CG, Inaba K, Steinman RM. Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med. 1989;169(3):1169-78. DOI: 10.1084/jem.169.3.1169
19. Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med. 1997;186(8):1183-7. DOI: 10.1084/jem.186.8.1183
20. Austyn JM. New insights into the mobilization and phagocytic activity of dendritic cells. J Exp Med. 1996;183(4):1287-92. DOI: 10.1084/jem.183.4.1287
21. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTLmediated protective tumor immunity. J Exp Med. 1996;183(1):283-7. DOI: 10.1084/jem.183.1.283
22. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52-8. DOI: 10.1038/nm0196-52
23. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostatespecific membrane antigen. Prostate. 1996;29(6):371-80. DOI: 10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B
24. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328-32. DOI: 10.1038/nm0398-328
25. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines [see comments]. J Exp Med. 1996;183(1):87-97. DOI: 10.1084/jem.183.1.87
26. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. Bone marrowderived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1(12):1297-302. DOI: 10.1038/nm1295-1297
27. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitopebased peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol. 1995;18(2):86-94.
28. Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G. Vaccination with mage-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190(11):1669-78. DOI: 10.1084/jem.190.11.1669
29. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996;184(2):465-72. DOI: 10.1084/jem.184.2.465
30. Gaiger A, Reese V, Disis ML, Cheever MA. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96(4):1480-9.
31. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivogenerated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93(7):2336-41.
32. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumours in mice vaccinated with professional antigen-presenting cells pulsed with tumour extracts. Int J Cancer. 1997;70(6):706-15. DOI: 10.1002/(SICI)1097-0215(19970317)70:6<706::AID-IJC13>3.0.CO;2-7
33. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med. 1994;180(1):1-4. DOI: 10.1084/jem.180.1.1
34. Parmiani G. Tumour immunity as autoimmunity: tumour antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol Today. 1993;14(11):536-8. DOI: 10.1016/0167-5699(93)90183-L
35. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139-49. DOI: 10.1084/jem.174.1.139
36. Archimbaud E, Bailly M, Doré JF. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol. 1991;77(3):328-34. DOI: 10.1111/j.1365-2141.1991.tb08579.x
37. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumour necrosis factor (TNF) activity. J Immunol Methods. 1988;115(1):61-9. DOI: 10.1016/0022-1759(88)90310-9
38. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods. 1983;64(3):313-20. DOI: 10.1016/0022-1759(83)90438-6
39. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87(3):453-8. DOI: 10.1111/j.1365-2141.1994.tb08297.x
40. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21(13):1673-9.
41. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med. 1983;157(3):884-97. DOI: 10.1084/jem.157.3.884
42. Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, Schmidt-Wolf IGH. Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19-9-protein. J Immunother. 2000;23(4):464-72. DOI: 10.1097/00002371-200007000-00010
43. Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von Rücker A, Sauerbruch T, Schmidt-Wolf IGH. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother. 2001;24(6):502-10. DOI: 10.1097/00002371-200111000-00007
44. Schui DK, Singh L, Schneider B, Knau A, Hoelzer D, Weidmann E. Inhibiting effects on the induction of cytotoxic T lymphocytes by dendritic cells pulsed with lysates from acute myeloid leukemia blasts. Leuk Res. 2002;26(4):383-9. DOI: 10.1016/S0145-2126(01)00141-2
45. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol. 1993;11:191-212. DOI: 10.1146/annurev.iy.11.040193.001203
46. Nossal GJ. Negative selection of lymphocytes. Cell. 1994;76(2):229-39. DOI: 10.1016/0092-8674(94)90331-X
47. Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti MC, Puccetti P. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol. 1997;158(8):3593-602.
48. Hämmerling GJ, Schönrich G, Ferber I, Arnold B. Peripheral tolerance as a multi-step mechanism. Immunol Rev. 1993;133:93-104. DOI: 10.1111/j.1600-065X.1993.tb01511.x
49. Jones LA, Chin LT, Longo DL, Kruisbeek AM. Peripheral clonal elimination of functional T cells. Science. 1990;250(4988):1726-9. DOI: 10.1126/science.2125368
50. Russell JH. Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol. 1995;7(3):382-8. DOI: 10.1016/0952-7915(95)80114-6
51. Schwartz RH. A cell culture model for T lymphocyte clonal anergy. Science. 1990;248(4961):1349-56. DOI: 10.1126/science.2113314
52. Essery G, Feldmann M, Lamb JR. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology. 1988;64(3):413-7.
53. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D,Corallo M, Perillo A, Scambia G, Pierelli L, Rutella S. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med. 2010;8:129. DOI: 10.1186/1479-5876-8-129
54. Schmidt J, Eisold S, Büchler MW, Märten A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother. 2004;53(11):1018-26. DOI: 10.1007/s00262-004-0554-4
55. Gütgemann S, Frank S, Strehl J, Schmidt-Wolf IGH. Cytokineinduced killer cells are type II natural killer T cells. GMS Ger Med Sci. 2007;5:Doc07. Available from: http://www.egms.de/en/gms/2007-5/000043.shtml
56. Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood. 1999;93(3):780-6.
57. Fujii S, Fujimoto K, Shimizu K, Ezaki T, Kawano F, Takatsuki K, Kawakita M, Matsuno K. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res. 1999;59(9):2150-8.
58. Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood. 1998;92(5):1677-84.
59. Serrano-López J, Sanchez-Garcia J, Serrano J, Alvarez-Rivas MA, Garcia-Castellano JM, Roman-Gomez J, Rosa Ode L, Herrera-Arroyo C, Torres-Gomez A. Nonleukemic myeloid dendritic cells obtained from autologous stem cell products elicit antileukemia responses in patients with acute myeloid leukemia. Transfusion. 2011;51(7):1546-55. DOI: 10.1111/j.1537-2995.2010.03042.x
60. Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Park KS, Lee IK, Chung IJ, Hwang TJ, Kim HJ. Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse afterautologous peripheral blood stem cell transplantation. J Clin Apher. 2004;19(2):66-70. DOI: 10.1002/jca.10080
61. Delluc S, Hachem P, Rusakiewicz S, Gaston A, Marchiol-Fournigault C, Tourneur L, Babchia N, Fradelizi D, Regnault A, Sang KH, Chiocchia G, Buzyn A. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response. Cancer Immunol Immunother. 2009;58(10):1669-77. DOI: 10.1007/s00262-009-0678-7
62. Weigel BJ, Panoskaltsis-Mortari A, Diers M, Garcia M, Lees C, Krieg AM, Chen W, Blazar BR. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Exp Hematol. 2006;34(10):1403-12. DOI: 10.1016/j.exphem.2006.05.011
63. Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol. 2005;129(3):340-9. DOI: 10.1111/j.1365-2141.2005.05477.x